Back to News
Market Impact: 0.48
Viking Therapeutics' obesity drug shows 22% weight loss in study
Source: reuters.com
Healthcare & BiotechProduct Launches
Viking Therapeutics reported that its experimental weekly GLP-1 obesity drug produced 22% average body-weight loss after 33 weeks in a maintenance study. The result is a strong clinical efficacy signal for Viking's obesity pipeline and could strengthen its competitive position in the high-growth GLP-1 market.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.70
Ticker Sentiment
VKTX0.85
More News
- Viking Therapeutics shares surge over 27% on weight loss drug maintenance data
- Viking Therapeutics Announces Positive Topline Results from Maintenance Study of GLP-1/GIP Agonist VK2735 Demonstrating the Promise of Multiple Maintenance Dosing Regimens
- Alibaba Higher on Chip News; On Holdings Football Move | Stock Movers
- Trump Says US Team Met With Iranians at UNGA
- Meta’s Muse AI is exploding in popularity—and already drawing heated backlash from another tech giant
- Qualcomm releases Android chip built for AI as memory shortage weighs on smartphone market